Overview
Insight Economics provided opinions in various jurisdictions related to the introduction of a generic sacubitril and valsartan drug which references the branded drug Entresto. The disputes centered around patents and Novartis seeking preliminary injunctions to block MSN from introducing its generic product until certain patent expirations.   

Challenge
Plaintiffs offered opinions regarding various ways in which MSN’s introduction would cause irreparable harm. Insight Economics rebutted the testimony of two experts in the field of economics.  

Results
The Federal Circuit heard an appeal regarding a district court opinion temporarily enjoining MSN and subsequently ordered Novartis to post an unsecured bond in the amount opined on by Insight Economics’ expert. The district judge highlighted various arguments offered by Insight Economics regarding the measurability of any potential harm and agreed that damages experts in the field could make appropriate estimates and adjustments to their models to account for various forecast differences.